Abnormally Short Erythrocyte LifeSpan in Three Patients with Primary Myelofibrosis Despite Successful Control of Splenomegaly

Ze-Lin Liu; Hou-De Zhang

doi:10.1016/j.amjms.2020.09.002

Abnormally Short Erythrocyte LifeSpan in Three Patients with Primary Myelofibrosis Despite Successful Control of Splenomegaly

Am J Med Sci. 2021 Feb;361(2):274-277. doi: 10.1016/j.amjms.2020.09.002. Epub 2020 Sep 3.

Authors

Ze-Lin Liu¹, Hou-De Zhang²

Affiliations

¹ Department of Hematology, Nanshan Hospital, Guangdong Medical University, Shenzhen, China.
² Department of Gastroenterology, Nanshan Hospital, Guangdong Medical University, Shenzhen, China. Electronic address: szkjk@126.com.

PMID: 32950178
DOI: 10.1016/j.amjms.2020.09.002

Abstract

Splenectomy is an elective operation for refractory anemia in patients with primary myelofibrosis (PMF). We found that 3/3 patients with PMF in our department continued to have very shortened erythrocyte (RBC) lifespans (35 days, 66 days, and 37 days, respectively) after treatment-alleviated splenomegaly. These outcomes suggest that intravascular hemolysis predominantly independent of hypersplenism may underlie, at least to some extent, peripheral hemolysis in patients with PMF. More cases studies are needed to elucidate the role of splenomegaly in PMF-associated anemia.

Keywords: Hemolysis; Hypersplenism; RBC lifespan.

Publication types

Case Reports
Review

MeSH terms

Aged
Anemia / blood*
Anemia / etiology
Erythrocytes*
Female
Hemolysis*
Humans
Hypersplenism
Male
Primary Myelofibrosis / blood*
Primary Myelofibrosis / complications